Biotechnology

Odyssey Therapeutics

TPG GP A Acquires Odyssey Therapeutics Shares at $18

SR One Capital Management Increases Holdings in Odyssey Therapeutics and Makes Open Market Trades

Jeffrey M. Leiden Buys Odyssey Therapeutics Shares and Increases Holding

Odyssey Therapeutics Director Lǐ Nán Buys $20 Million of Common Stock

Odyssey Therapeutics Director Shelley Chu Buys 11,111 Shares During IPO

Odyssey Therapeutics Conducts Unregistered Private Equity Sale

ODTX.US released FY2024 Annual Earnings on April 17, 2026 (BJT) with actual revenue of USD 4.472 M and EPS of USD -16.6295

ODTX.US released FY2025 Annual Earnings on April 17 (BJT), actual revenue USD 2.976 M, actual EPS USD -5.1589

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MicroAlgo

MetaVia

Tradr 2X Long XNDU Daily ETF

ODTX

Simeon George, M.D., of SR One Capital Management, disclosed an 8.0% stake in Odyssey Therapeutics, Inc. following its IPO on May 11, 2026. The investment combines IPO purchases and conversions of preferred stock. SR One holds the shares for investment purposes and has signed a 180-day lock-up agreement starting May 7, 2026, restricting sales. SR One focuses on early and growth-stage biotech companies.

TradingView

GlaxoSmithKline plc

GSK plc Sponsored ADR

Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake

TPG GP A, LLC disclosed a 7.8% stake in Odyssey Therapeutics, Inc. through a $25 million private placement. The investment allows TPG to influence Odyssey's strategy, although it currently has no plans for changes. TPG purchased 1,388,889 shares at $18 each and holds rights to register and resell its shares, with potential future actions including operational shifts or board changes to enhance shareholder value.

TPG GP A, LLC Discloses Investment at Odyssey Therapeutics with 7.8% Stake

Jeito II S.L.P., a French investment fund, has acquired a 7.8% stake in Odyssey Therapeutics, Inc., purchasing 1,388,888 shares at $18 during the company's IPO. This investment allows Jeito to exert significant influence, with an executive already on Odyssey's board. Jeito plans to review its position and may adjust its holdings while maintaining an active dialogue with Odyssey's management.

Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake

Odyssey Therapeutics(ODTX.US)

Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake

TPG GP A, LLC Discloses Investment at Odyssey Therapeutics with 7.8% Stake

Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake